Výsledky vyhledávání - "Karl Waßmann"

Akademický článek

A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

Autor: Philip Friedlander, Kevin Wood, Karl Wassmann, Alan M. Christenfeld, Nina Bhardwaj, William K. Oh

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)

Abstract Background Anti-CTLA-4 immune checkpoint blockade is associated with immune-related adverse events (irAEs). Grade 3–4 diarrhea/colitis is the most frequent irAE requiring treatment discontinuation. Predicting high-risk diarrhea/colitis pat

Externí odkaz: https://doaj.org/article/b5a2a6255021438d9301ee442a1aa293

Zobrazit plný text záznamu

Akademický článek

Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

Autor: Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj, William K. Oh

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)

Abstract Background Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to facilitate clinicall

Externí odkaz: https://doaj.org/article/e871d5f254414ab0bdf89b06056cc7a9

Zobrazit plný text záznamu

Akademický článek

Blood-based biomarkers of aggressive prostate cancer.

Autor: Men Long Liong, Chun Ren Lim, Hengxuan Yang, Samuel Chao, Chin Wei Bong, Wing Seng Leong, Prashanta Kumar Das, Chit Sin Loh, Ban Eng Lau, Choon Geok Yu, Edie Jian Jiek Ooi, Robert K Nam, Paul D Allen, Graeme S Steele, Karl Wassmann, Jerome P Richie, Choong Chin Liew

Publikováno v: PLoS ONE, Vol 7, Iss 9, p e45802 (2012)

PURPOSE: Prostate cancer is a bimodal disease with aggressive and indolent forms. Current prostate-specific-antigen testing and digital rectal examination screening provide ambiguous results leading to both under-and over-treatment. Accurate, consist

Externí odkaz: https://doaj.org/article/300d732875804017bd26810979b0c534

Zobrazit plný text záznamu

Akademický článek

Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma.

Autor: Yuchun Luo, Steven Robinson, Junichi Fujita, Lisa Siconolfi, Jay Magidson, Carl K Edwards, Karl Wassmann, Kathleen Storm, David A Norris, Danute Bankaitis-Davis, William A Robinson, Mayumi Fujita

Publikováno v: PLoS ONE, Vol 6, Iss 6, p e20971 (2011)

Developing analytical methodologies to identify biomarkers in easily accessible body fluids is highly valuable for the early diagnosis and management of cancer patients. Peripheral whole blood is a "nucleic acid-rich" and "inflammatory cell-rich" inf

Externí odkaz: https://doaj.org/article/9232f5c6edea4dff9e9c88cc98796c1f

Zobrazit plný text záznamu

Data from Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

Autor: Philip Friedlander, William K. Oh, John Kirkwood, David Fisher, Karl Wassmann, Yichun Fu, Sara Harcharik, Ellen de Moll, Bobby Liaw, Jay Magidson, Yvonne Saenger

Purpose: Tremelimumab (ticilimumab, Pfizer), is a monoclonal antibody (mAb) targeting cytotoxic T lymphocyte–associated antigen-4 (CTLA-4). Ipilimumab (Yervoy, BMS), another anti-CTLA-4 antibody, is approved by the U.S. Federal Drug Administration

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29db8ca29156dfc5f8d157e4296b96ec
https://doi.org/10.1158/1078-0432.c.6522014

Zobrazit plný text záznamu

Autor: Nina Bhardwaj, William Oh, Alan M. Christenfeld, Philip Friedlander, Kevin Wood, Karl Wassmann

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)

Anti-CTLA-4 immune checkpoint blockade is associated with immune-related adverse events (irAEs). Grade 3–4 diarrhea/colitis is the most frequent irAE requiring treatment discontinuation. Predicting high-risk diarrhea/colitis patients may facilitate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a945e4628ac0d4b8ad5a4d26179d326
https://pubmed.ncbi.nlm.nih.gov/30227886

Zobrazit plný text záznamu

Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

Autor: Nina Bhardwaj, William Oh, Alan M. Christenfeld, Karl Wassmann, John M. Kirkwood, Philip Friedlander, Chrisann Kyi, David E. Fisher

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)

Background Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to facilitate clinically effecti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5352be0fb85100df2ce1a35f2401cad6
https://doi.org/10.1186/s40425-017-0272-z

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání